Cargando…

Model-Based Optimisation of Deferoxamine Chelation Therapy

PURPOSE: Here we show how a model-based approach may be used to provide further insight into the role of clinical and demographic covariates on the progression of iron overload. The therapeutic effect of deferoxamine is used to illustrate the application of disease modelling as a means to characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellanti, Francesco, Del Vecchio, Giovanni C., Putti, Maria C., Cosmi, Carlo, Fotzi, Ilaria, Bakshi, Suruchi D., Danhof, Meindert, Della Pasqua, Oscar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709373/ https://www.ncbi.nlm.nih.gov/pubmed/26555666 http://dx.doi.org/10.1007/s11095-015-1805-0

Ejemplares similares

The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments
por: Sahota, Tarjinder, et al.
Publicado: (2015)

Characterizing QT interval prolongation in early clinical development: a case study with methadone
por: Dubois, Vincent F. S., et al.
Publicado: (2017)

The iron chelator deferoxamine decreases myeloma cell survival
por: Yang, Feifei, et al.
Publicado: (2021)

Chelating the valley of death: Deferoxamine’s path from bench to wound clinic
por: Parker, Jennifer B., et al.
Publicado: (2023)

Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
por: Leung, Nelson, et al.
Publicado: (2009)

Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator
por: Bellotti, Denise, et al.
Publicado: (2021)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

Modelling and simulation as research tools in paediatric drug development
por: Bellanti, Francesco, et al.
Publicado: (2011)

Characterisation of individual ferritin response in patients receiving chelation therapy
por: Borella, Elisa, et al.
Publicado: (2022)

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
por: Bellanti, Francesco, et al.
Publicado: (2011)

Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction
por: Ikeda, Yasumasa, et al.
Publicado: (2014)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
por: Lazaridou, Maria, et al.
Publicado: (2020)

Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats
por: Feng, Yunfei, et al.
Publicado: (2023)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells
por: Fujisawa, Koichi, et al.
Publicado: (2022)

Comparison Between Hesperidin, Coumarin, and Deferoxamine Iron Chelation and Antioxidant Activity Against Excessive Iron in the Iron Overloaded Mice
por: Aalikhani, Mahdi, et al.
Publicado: (2022)

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
por: Roy, Jyoti, et al.
Publicado: (2021)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models
por: Danhof, Meindert
Publicado: (2015)

Markers of exacerbation severity in chronic obstructive pulmonary disease
por: Franciosi, Luigi G, et al.
Publicado: (2006)

Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm
por: Taneja, A., et al.
Publicado: (2017)

Deferoxamine therapy for intracerebral hemorrhage: A systematic review
por: Zeng, Liling, et al.
Publicado: (2018)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians
por: Vermeulen, Eric, et al.
Publicado: (2016)

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
por: Alpendurada, Francisco, et al.
Publicado: (2012)

Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature
por: Di Nicola, Maura, et al.
Publicado: (2015)

Deferoxamine-Modified Hybrid Materials for Direct Chelation of Fe(III) Ions from Aqueous Solutions and Indication of the Competitiveness of In Vitro Complexing toward a Biological System
por: Pawlaczyk, Mateusz, et al.
Publicado: (2021)

Abstract: Deferoxamine Increases Breast Cancer Radiosensitivity
por: Ranganathan, Kavitha, et al.
Publicado: (2018)

Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease
por: Kosyakovsky, Jacob, et al.
Publicado: (2021)

Deferoxamine Reduces Inflammation and Osteoclastogenesis in Avulsed Teeth
por: Lee, Ko Eun, et al.
Publicado: (2021)

Iron Neurotoxicity and Protection by Deferoxamine in Intracerebral Hemorrhage
por: Li, Zhe, et al.
Publicado: (2022)

Deferoxamine inhibition of malaria is independent of host iron status
Publicado: (1988)

Comparison of the effect of vanadium and deferoxamine on acetaminophen toxicity in rats
por: Najafzadeh, H., et al.
Publicado: (2011)

Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
por: Chen, Jianfang, et al.
Publicado: (2013)

Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism
por: Yang, Yujing, et al.
Publicado: (2018)

The effect of deferoxamine injection on composite graft survival in rabbits
por: Ramli, Rianto Noviady, et al.
Publicado: (2020)

Effects of deferoxamine on intrinsic colistin resistance of Proteus mirabilis
por: Erinmez, Mehmet, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4llv07qvqq8qcrhtnsltlsug1l